| **Variable  Stratified Variable** | **No Severe PGD\* (n = 54)** | **Severe PGD\* (n = 8)** | **Total** | **p†** |
| --- | --- | --- | --- | --- |
| demographics\_age\_tpx | 56 [46–61] | 59 [48–63] | 57 [46–61] | 0.508 |
| Demographics Sex |  |  |  |  |
| *Male* | 37 (69%) | 5 (62%) | 42 (68%) | 0.705 |
| *Female* | 17 (31%) | 3 (38%) | 20 (32%) | - |
| Demographics Race |  |  |  |  |
| *Black* | 31 (57%) | 2 (25%) | 33 (53%) | 0.204 |
| *White* | 18 (33%) | 5 (62%) | 23 (37%) | - |
| *Asian* | 3 (6%) | 1 (12%) | 4 (6%) | - |
| *Hispanic* | 2 (4%) | 0 (0%) | 2 (3%) | - |
| demographics\_BMI | 26 ± 5 | 29 ± 3 | 26 ± 5 | **0.028** |
| comorbidities\_smoking\_hx: Y | 15 (28%) | 3 (38%) | 18 (29%) | 0.681 |
| comorbidities\_DM: Y | 18 (33%) | 4 (50%) | 22 (35%) | 0.438 |
| comorbidities\_prior\_cardiac\_surg: Y | 20 (37%) | 3 (38%) | 23 (37%) | >0.999 |
| Recipient NICM ICM Cong |  |  |  |  |
| *NICM* | 40 (74%) | 6 (75%) | 46 (74%) | >0.999 |
| *ICM* | 11 (20%) | 2 (25%) | 13 (21%) | - |
| *Congenital* | 3 (6%) | 0 (0%) | 3 (5%) | - |
| preop\_temp\_MCS: Y | 33 (61%) | 5 (62%) | 38 (61%) | >0.999 |
| preop\_IABP: Y | 2 (4%) | 0 (0%) | 2 (3%) | >0.999 |
| preop\_imeplla5.5: Y | 32 (59%) | 4 (50%) | 36 (58%) | 0.710 |
| preop\_VA\_ECMO: Y | 2 (4%) | 2 (25%) | 4 (6%) | 0.077 |
| preop\_LVAD: Y | 10 (19%) | 2 (25%) | 12 (19%) | 0.645 |
| recipient\_UNOS\_status | 2 [2–2] | 2 [2–4] | 2 [2–2] | 0.416 |
| preop\_PVR | 2 [1–3] | 2 [2–3] | 2 [1–3] | 0.787 |
| rx\_preop\_inotrope: Y | 37 (69%) | 4 (50%) | 41 (66%) | 0.426 |
| rx\_preop\_amiodarone: Y | 17 (31%) | 3 (38%) | 20 (32%) | 0.705 |
| preop\_RADIAL\_calc | 3 [2–4] | 3 [2–4] | 3 [2–4] | 0.750 |
| preop\_labs\_albumin | 4 [3–4] | 4 [3–4] | 4 [3–4] | 0.982 |
| preop\_labs\_alkphos | 78 [63–89] | 69 [53–79] | 73 [62–89] | 0.352 |
| preop\_labs\_ALT | 20 [13–30] | 45 [23–50] | 22 [14–40] | 0.082 |
| preop\_labs\_AST | 22 [19–33] | 34 [29–42] | 25 [19–35] | **0.047** |
| preop\_labs\_bilirubin | 1 [0–1] | 1 [1–1] | 1 [0–1] | 0.441 |
| preop\_labs\_creatinine | 1 [1–2] | 1 [1–1] | 1 [1–2] | 0.425 |
| preop\_labs\_GFR | 61 ± 25 | 69 ± 30 | 62 ± 26 | 0.532 |
| preop\_labs\_Hgb | 11 ± 2 | 10 ± 3 | 11 ± 2 | 0.810 |
| preop\_labs\_Plt | 183 [156–228] | 160 [143–207] | 180 [154–227] | 0.372 |
| preop\_labs\_sodium | 134 ± 4 | 133 ± 4 | 134 ± 4 | 0.923 |
| preop\_labs\_WBC | 7 [6–9] | 9 [8–10] | 7 [6–9] | 0.133 |
| *Statistical Methods: For continuous variables, normality was assessed using the Shapiro–Wilk test (when enabled). Normally distributed variables were summarized as mean ± SD and compared using Welch's t-test for two-group comparisons or one-way ANOVA for three-group comparisons. Non-normally distributed or user-specified ordinal variables were summarized as median [IQR] and compared using the Wilcoxon rank-sum test (two groups) or Kruskal–Wallis test (three groups). Categorical variables were summarized as n (%) and compared using Chi-squared tests or Fisher's exact tests when expected counts were <5. For binary categorical variables, odds ratios with 95% confidence intervals were computed using Fisher's exact or Wald methods, as appropriate. Approximate p-values were used for non-parametric tests with tied data.  \*- All values are presented as mean ± SD for normally distributed continuous variables, median [IQR] for non-normally distributed continuous or ordinal variables, and n (%) for categorical variables. †- Welch's t-test was used to compute p-values for normally distributed continuous variables. Wilcoxon Rank Sum test was used to compute p-values for non-normally distributed continuous or ordinal variables. Fisher's exact or chi-squared test was used to compute p-values for categorical variables, as appropriate. p-values are bolded for p ≤ 0.05.* | | | | |